BOZEN, Sud-Tirol, Italy, December 3, 2010 /PRNewswire/ -- Health Robotics today announced that it recently signed an exclusive cooperation agreement for Grifols to significantly contribute to its I.V. Room of the Future Initiative with its Misterium state-of-the-art Clean Room products and I.V. Therapy and Clinical Nutrition scientific knowledge and experience. The agreement also includes the appointment of Grifols' scientific expert Dr. Oriol Prat as an additional member of Health Robotics' Scientific Advisory Board, where he will join representatives of The Cleveland Clinic Foundation, Ochsner Clinic, Sutter Health, USC University Hospital, and The University of Chicago Medical Center.
"Grifols has designed and constructed more than 1.2 million square feet of clean rooms worldwide and managed more than 150 modular clean room installations at hospitals. After witnessing the outstanding combined results of the joint implementation of Misterium and i.v.STATION at Vall d'Hebron University Hospital in Barcelona, I was convinced that global hospitals stand to greatly benefit from the synergies between the respective companies' experience, products, and services within the I.V. Room Technology sector," stated Gaspar DeViedma, Health Robotics' Executive Vice President.
"Among the advantages of Misterium modular clean rooms over conventional construction include their flexible, convenient and fast construction, usually within 2 to 4 weeks, with minimal disruption to the pharmacy's operations, ease of maintenance, GMP compliance, and integrated training tools and workflow analysis," stated Xavier Guix, Vice President of Marketing for Grifols' Hospital System Division.
About Grifols S.A.:
Grifols is a Spain-based company engaged in the healthcare sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6.000 employees, 26 subsidiaries with combined gross revenues over EUR800 million, and a EUR3 billion market capitalization. For more information, please visit http://www.grifols.com
About Health Robotics:
Health Robotics is the undisputed global leading supplier of life-critical intra-venous medication robots, providing healthcare facilities in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(R) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs], i.v.SOFT(R) [manual compounding software], MEDarchiver (R) [clinical information system], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug-exchange errors, decrease other medical errors and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more company information, please visit http://www.health-robotics.com/
For additional information, please contact: Claudia Flaim, Marketing Coordinator firstname.lastname@example.org Phone: +39-0471-200-372
SOURCE Health Robotics